Drug Approval | May 18, 2022
Themis Medicare gets add on approval for Viralex
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Subscribe To Our Newsletter & Stay Updated
